Versant Capital Management Inc Raises Stock Position in DaVita Inc. (NYSE:DVA)

Versant Capital Management Inc lifted its stake in DaVita Inc. (NYSE:DVA) by 58.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 457 shares of the company’s stock after buying an additional 169 shares during the period. Versant Capital Management Inc’s holdings in DaVita were worth $68,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DVA. JPMorgan Chase & Co. increased its position in shares of DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after purchasing an additional 92,014 shares in the last quarter. Harvard Management Co. Inc. purchased a new position in DaVita during the 2nd quarter worth approximately $55,115,000. KBC Group NV lifted its stake in DaVita by 27.3% in the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after buying an additional 67,250 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of DaVita by 23.9% in the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company’s stock valued at $47,874,000 after acquiring an additional 56,389 shares during the period. Finally, Andra AP fonden grew its position in shares of DaVita by 9.0% during the second quarter. Andra AP fonden now owns 192,300 shares of the company’s stock worth $26,647,000 after acquiring an additional 15,800 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Price Performance

Shares of DVA opened at $152.82 on Monday. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The stock’s 50 day moving average is $155.10 and its two-hundred day moving average is $151.71. DaVita Inc. has a twelve month low of $103.40 and a twelve month high of $169.51. The firm has a market capitalization of $12.53 billion, a PE ratio of 16.49, a P/E/G ratio of 0.86 and a beta of 0.90.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter last year, the firm earned $2.85 earnings per share. The firm’s quarterly revenue was up 4.6% compared to the same quarter last year. Research analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Truist Financial increased their price objective on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, DaVita has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.